4.64

2.43% 0.11

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $4.64, with a volume of 2.74M. It is up +2.43% in the last 24 hours and up +2.20% over the past month. Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Previous Close:

$4.53

Open:

$4.5

24h Volume:

2.74M

Relative Volume:

0.97

Market Cap:

$1.27B

Revenue:

$6.31M

Net Income/Loss:

$-99.93M

P/E Ratio:

-13.09

EPS:

-0.3544

Net Cash Flow:

$-85.14M

1W Performance:

-0.64%

1M Performance:

+2.20%

6M Performance:

+42.33%

1Y Performance:

+184.66%

1-Day Range:

$4.475

$4.70

1-Week Range:

$4.44

$4.70

52-Week Range:

$1.05

$6.02

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2026-03-04

Latest SEC Filings

TSHA's Discussions on Twitter

Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TSHA Taysha Gene Therapies Inc	4.64	1.24B	6.31M	-99.93M	-85.14M	-0.3544
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-25	Initiated	Raymond James	Strong Buy
Jul-11-25	Initiated	BofA Securities	Buy
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Apr-09-24	Initiated	Piper Sandler	Overweight
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

Mar 03, 2026

TSHA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Taysha Gene faces earnings test as Rett trial advances By Investing.com - Investing.com South Africa

Mar 03, 2026

Taysha Gene faces earnings test as Rett trial advances - Investing.com

Mar 03, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Earns Buy Rating from Needham & Company LLC - MarketBeat

Mar 03, 2026

TSHA: Needham Reiterates Buy Rating with Price Target Maintained | TSHA Stock News - GuruFocus

Mar 03, 2026

Feb 28, 2026

TSHA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Feb 28, 2026

Feb 27, 2026